Pharmacogenomics of membrane transporters: Past, present and future

Pharmacogenomics

Volumn 11, Issue 4, 2010, Pages 475-479

  Yee, Sook Wah ^a   Chen, Ligong ^a   Giacomini, Kathleen M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Coding variant; Genome wide association study; Membrane transporter; Noncoding variant; Pharmacogenomics; Polymorphism

Indexed keywords

ABC TRANSPORTER; ATORVASTATIN; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; CISPLATIN; CITALOPRAM; DOCETAXEL; DRUG METABOLIZING ENZYME; FEXOFENADINE; FLUOXETINE; IMATINIB; IRINOTECAN; METFORMIN; METHOTREXATE; MICRORNA; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; PAROXETINE; PITAVASTATIN; PRAVASTATIN; REPAGLINIDE; RISPERIDONE; ROSUVASTATIN; SIMVASTATIN; TENOFOVIR;

3' UNTRANSLATED REGION; CLINICAL STUDY; DNA POLYMORPHISM; DRUG RESPONSE; FUNCTIONAL GENOMICS; GENE EXPRESSION; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; NOTE; PHARMACOGENOMICS; PHENOTYPE; PROTEIN RNA BINDING; SINGLE NUCLEOTIDE POLYMORPHISM;

GENOME, HUMAN; HUMANS; MEMBRANE TRANSPORT PROTEINS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHARMACOLOGY, CLINICAL; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77950355185     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.22     Document Type: Note

References (22)

1. Gradhand U, Kim RB: Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2). Drug Metab. Rev. 40(2), 317-354 (2008).
2. Leabman MK, Huang CC, DeYoung J et al.: Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc. Natl Acad. Sci. USA 100(10), 5896-5901 (2003).
3. Urban TJ, Sebro R, Hurowitz EH et al.: Functional genomics of membrane transporters in human populations. Genome Res. 16(2), 223-230 (2006).
4. Maeda K, Sugiyama Y: Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab. Pharmacokinet. 23(4), 223-235 (2008).
5. Hoffmeyer S, Burk O, von Richter O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 97(7), 3473-3478 (2000).
6. Kimchi-Sarfaty C, Oh JM, Kim IW et al.: A 'silent' polymorphism in the MDR1 gene changes substrate specifcity. Science 315(5811), 525-528 (2007).
7. Hesselson SE, Matsson P, Shima JE et al.: Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specifc expression and promoter activity predict variation. PLoS One 4(9), E6942 (2009).
8. Choi JH, Yee SW, Kim MJ et al.: Identifcation and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1. Pharmacogenet. Genomics 19(10), 770-780 (2009).
9. Tahara H, Yee SW, Urban TJ et al.: Functional genetic variation in the basal promoter of the organic cation/carnitine transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5). J. Pharmacol. Exp. Ther. 329(1), 262-271 (2009).
10. Yee SW, Shima JE, Hesselson S et al.: Identifcation and characterization of proximal promoter polymorphisms in the human concentrative nucleoside transporter 2 (SLC28A2). J. Pharmacol. Exp. Ther. 328(3), 699-707 (2009).
11. To KK, Zhan Z, Litman T, Bates SE: Regulation of ABCG2 expression at the 3́ untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. Mol. Cell Biol. 28(17), 5147-5161 (2008).
12. Pan YZ, Morris ME, Yu AM: MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol. Pharmacol. 75(6), 1374-1379 (2009).
13. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH: Genetic variation in the multidrug and toxin extrusion 1 transporter protein infuences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 58(3), 745-749 (2009).
14. Sanna S, Busonero F, Maschio A et al.: Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia. Hum. Mol. Genet. 18(14), 2711-2718 (2009).
15. Murabito JM, Rosenberg CL, Finger D et al.: A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study. BMC Med. Genet. 8(Suppl. 1), S6 (2007).
16. Tregouet DA, Konig IR, Erdmann J et al.: Genome-wide haplotype association study identifes the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat. Genet. 41(3), 283-285 (2009).
17. Link E, Parish S, Armitage J et al.: SLCO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med. 359(8), 789-799 (2008).
18. Shu Y, Brown C, Castro RA et al.: Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin. Pharmacol. Ther. 83(2), 273-280 (2008).
19. Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M: Different effects of the ABCG2 c.421CA SNP on the pharmacokinetics of fuvastatin, pravastatin and simvastatin. Pharmacogenomics 10(10), 1617-1624 (2009).
20. Ho RH, Choi L, Lee W et al.: Effect of drug transporter genotypes on pravastatin disposition in European-and African-American participants. Pharmacogenet. Genomics 17(8), 647-656 (2007).
21. Schadt EE, Molony C, Chudin E et al.: Mapping the genetic architecture of gene expression in human liver. PLoS Biol. 6(5), E107 (2008).
22. Kroetz DL, Yee SW, Giacomini KM: The pharmacogenomics of membrane transporters project: research at the interface of genomics and transporter pharmacology. Clin. Pharmacol. Ther. 87(1), 109-116 (2010).